Physician profile
Sandra Aristea Hyder
NPI 1821470071
$2,507.01
in general payments reported to CMS, 2019-2025
14 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 96% of Critical Care Medicine (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.49 · 2023: $224 · 2024: $500 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $889.16 | 2023-2025 | Repatha, Repatha |
| Abiomed | $415.26 | 2025 | |
| Atricure, INC. | $268.69 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System, Atricure Cryoice Cryoablation System (Cryo2) |
| Gilead Sciences, INC. | $224.89 | 2024-2025 | Livdelzi, Epclusa |
| Abbott Laboratories | $134.08 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Corcept Therapeutics | $122.98 | 2025 | Korlym |
| Mallinckrodt Hospital Products INC. | $107.73 | 2025 | Terlivaz |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $93.89 | 2023 | Andexxa, Farxiga |
| Olympus America INC. | $54.29 | 2022-2024 | |
| Edwards Lifesciences Corporation | $29.97 | 2024 | |
| W. L. Gore & Associates, INC. | $28.33 | 2023 | Gore Tag Thoracic Branch Endoprosthesis |
| Vapotherm INC | $21.15 | 2025 | Vapotherm |
| Ucb, INC. | $20.40 | 2025 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.